IntroDuctIon
Human induced pluripotent stem cells (hiPSCs) can be derived from somatic cells through a reprogramming process driven by overexpression of a defined set of transcription factors 1, 2 . These hiPSCs share the properties of self-renewal and pluripotency with human embryonic stem cells (hESCs), and can therefore be used to generate unlimited quantities of differentiated cell types of all three germ layers, including cardiac cells, neural cells and hepatic cells. hiPSCs can be generated from patients of virtually any genetic background, including those with disease-conferring genetic mutations [3] [4] [5] . In contrast, the derivation of hESCs from different genetic backgrounds is challenging because human embryo use is limited and ethically debated. The production of patient-specific and disease-specific hiPSCs enables a variety of downstream applications, including drug screening, disease modeling, pathogenesis studies and regenerative medicine therapies.
However, traditional approaches to deriving hiPSCs require the use of retroviruses or lentiviruses that integrate reprogramming genes into the host genome. Random integration of the reprogramming genes may result in insertional mutagenesis that causes malignant transformation of a clonal cell population 6 . In addition, some of the genes used in the reprogramming process are known proto-oncogenes, and incomplete silencing of these transgenes may result in unknown adverse effects. These challenges have been partially circumvented in mice by the development of non-integrating viral 7 , nonviral episomal 8 and excisional 9, 10 techniques for reprogramming. Yet clinical translation of these techniques for safer iPSC derivation is challenging because human cells are relatively more resistant to nonviral transfection and are not immediately available in large quantities. Although hiPSCs may be generated by lentiviral transduction with subsequent Cre-loxP excision of reprogramming factors 3 , residual vector sequences will be left behind in the genome. Transgene-free hiPSCs have been derived from neonatal foreskin fibroblasts using a combination of three episomal plasmids expressing seven reprogramming factors 11 . Alternatively, transgene-free hiPSCs can be derived from fetal or neonatal cells by repeated transduction of proteins in the presence of chemical treatments (e.g., valproic acid) 12 . However, none of the aforementioned techniques for transgene-free hiPSC derivation has been demonstrated with adult donors, a more clinically relevant population. In this study, we describe in detail a protocol for the derivation of transgene-free hiPSCs with a nonviral minicircle DNA reprogramming construct used in conjunction with human adipose stromal cells (hASCs) 13 . This technique is advantageous in translational studies because somatic cells from human adults can be reprogrammed in the absence of genomic modification, viral sequences or proto-oncogenes (such as c-Myc), effectively mitigating safety concerns expansion to a large starting population of hASCs. For example, reprogramming can start as early as 24 h after the liposuction procedure with a large starting cell population of up to 20-30 million cells, whereas 3-4 weeks are required following punch skin biopsy for expansion of the dermal fibroblasts. hASCs are a heterogeneous group of multipotent progenitor cells that can differentiate into adipogenic, osteogenic, chondrogenic and myogenic cell lineages 19, 20 . As such, hASCs express relatively high levels of the c-Myc and Klf4 genes, which may underlie the relative ease of their induction to pluripotency. Users should note that the protocol described here has been most successfully applied when using hASCs as the starting cell source, although neonatal fibroblasts (e.g., IMR90) can also be used with lower efficiency.
Minicircle vectors.
Minicircle vectors are supercoiled DNA molecules free of bacterial plasmid backbone elements, such as an origin of replication and an antibiotic resistance gene. They primarily consist of a eukaryotic expression cassette, and therefore do not activate exogenous silencing mechanisms to the same extent as plasmids. Therefore, minicircle vectors benefit from higher transfection efficiencies and more stable ectopic transgene expression than plasmid DNA (Fig. 2) 
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. The pMC.
LGNSO plasmid is the parental DNA construct that is used to produce minicircle reprogramming vector in the initial steps of this protocol (Steps 1-13). Parental plasmid DNA (e.g., pMC.LGNSO) that produces minicircle vectors may be conceptually divided into two parts separated by attB and attP recognition sequences. Intermolecular recombination between the attB and attP sequences catalyzed by the ΦC31 integrase (Step 9) yields a minicircle vector separated from the remainder of the plasmid (Fig. 3) . The minicircle vector contains the reprogramming genes OCT4, SOX2, NANOG and LIN28. This expression cassette is isolated and purified from the bacterial suspension (Steps 1-12) before being transfected into somatic cells to induce reprogramming (Step 13-47). The other part of the pMC.LGNSO parental plasmid contains bacterial plasmid backbone elements (e.g., the origin of replication and antibiotic resistance cassette), as well as the ΦC31 integrase and I-SceI restriction enzyme expression cassettes under the control of an l-arabinose-inducible promoter. This part of the plasmid is linearized by I-SceI endonucleolytic cleavage and subsequently degraded (Step 9), allowing isolation of pure minicircle DNA by common plasmid purification procedures (e.g., Qiagen plasmid purification kits). Yield and purity of the minicircle DNA preparation may be optimized by use of plasmids encoding multiple copies of ΦC31 integrase 22 , or by the use of Escherichia coli strains that encode l-arabinose-inducible I-SceI as part of the bacterial genome (e.g., E. coli strain ZYCY10P3S2T). The purified minicircle expression cassette contains the four reprogramming genes plus enhanced green fluorescent protein (EGFP) separated by 2A ribosomal slippage sequences, thereby allowing the equimolar expression of all five proteins from a single RNA transcript (Fig. 3) . This protocol requires transfection of hASCs with the minicircle preparation three times. First, cells are electroporated to optimize transfection efficiency, then sorted by flow cytometry to enrich for successfully transfected cells, and then finally transfected twice using cationic lipids (e.g., with Lipofectamine) to optimize cell survival.
FACS.
Detailed description of the flow cytometric enrichment of EGFP + hASCs after the first electroporation (
Step 37) will vary by institution and is beyond the scope of this protocol. Fortunately, well-established protocols for sorting of EGFP + cells are readily available 23, 24 . For the initial sorting procedure, 5 × 10 5 untransfected hASCs should be trypsinized and resuspended in fluorescenceactivated cell sorting (FACS) buffer alongside the transfected hASCs to set up the gating parameters. Once set, the gating parameters can be saved and untransfected hASCs are no longer needed. We used a FACSAria equipped with FACSDiva software for cell analysis and sorting (http://facs.stanford.edu/). Forward scatter (~82 V) and side Screening of the resulting hiPSC lines. Expression of the minicirclederived reprogramming cassette can be easily monitored throughout the procedure by EGFP fluorescence. At the conclusion of the procedure, however, bona fide hiPSC colonies will no longer be dependent on exogenous reprogramming factor expression, and will thereby be EGFP negative. The pluripotency of the derived hiPSC lines can be verified using standard assays described in detail elsewhere, including reverse transcriptase PCR (RT-PCR) and immunocytochemistry for pluripotent markers, as well as embryoid body differentiation and teratoma formation 25 . In addition to these standard protocols, the resulting hiPSCs can be screened for rare integration events by a simple PCR-based assay for the presence of the transgene in genomic DNA. The minicirclederived reprogramming cassette contains the LIN28, NANOG, SOX2 and OCT4 cDNA sequences in succession (Fig. 3) , whereas endogenous genomic DNA loci expressing these genes contain introns and are present on disparate chromosomes. Therefore, PCR of extracted genomic DNA using primers annealing to two contiguous minicircle reprogramming genes (e.g., SOX2 and OCT4) can readily identify rare integration events of the transgene into genomic DNA (Steps 57-60). Steps 52-61. Nuclear antigens requiring permeabilization, such as Oct4, Nanog and Sox2, were stained using Alexa Fluor 546-conjugated secondary antibody (red emission), while cell surface antigens Tra-1-60, Tra-1-81 and SSEA4 were stained using Alexa Fluor 488-conjugated secondary antibody (green emission). Merged images (far right) show localization of Tra-1-60, Tra-1-81 and SSEA4 antigens (green) to the cell surface in contrast to the nuclear DAPI stain (blue). (e) qPCR analysis of three undifferentiated minicircle-derived hiPSC lines compared with H9 hESCs, hASCs and 293-MC negative control (HEK 293 cells 24 h after transfection with the minicircle vector). Robust expression of pluripotency markers including endogenous (endo) OCT4, SOX2, NANOG, lIN28, ERAS, TLE1 (also known as ESG1), C6ORF221 (also known as ECAT1) and TDGF1 (also known as CRIPTO) was observed in the hiPSC and hESC lines, with 18S rRNA serving as a positive control. Genomic DNA was also isolated to screen for integration of the minicircle vector using primers specific for the Oct4-Sox2 transgene (bottom). Reproduced with permission from reference 13. . Store at 4 °C for ~2 weeks. 0.075% Type II collagenase Add 75 mg of type II collagenase to 100 ml of ddH 2 O (0.075% (wt/vol)) and filter-sterilize using a 0.44-µm vacuum-driven filter system. Make 10-ml aliquots of solution and store them at − 20 °C for up to 2 months. Gelatin solution Dissolve 0.5 g gelatin powder in 500 ml of distilled water; autoclave and store at 4 °C for up to 2 months. Gelatin-coated culture dishes Add a sufficient volume of gelatin solution to cover the surface of the plate or well. Incubate the dish for at least 30 min at 37 °C. Before use, aspirate excess gelatin solution. 3| Begin transforming the E. coli strain (ZYCY10P3S2 or TOP10) with pMC.
LGNSO plasmid by adding 100 pg to 50 ng of plasmid to a 50-µl aliquot containing 1 × 10 9 colony-forming units (c.f.u.) of chemically competent E. coli. Place on ice for 10 min.
4| Heat-shock in 42 °C water bath for 30 s. Next, place on ice for 2 min.
5|
Spread transformed E. coli on a prewarmed LB-agar kanamycin-selective plate. Incubate overnight 12-16 h at 37 °C.
6|
The next day, inoculate 5 ml of LB broth containing kanamycin (50 µg ml − 1 ) with a colony from the freshly streaked plate. Incubate this starter culture at 37 °C with agitation at 250 r.p.m. for 8 h. 
8|
Inoculate 100 µl of the starter culture from Step 5 into 400 ml of TB prepared in Step 6 and incubate overnight for 16-18 h at 37 °C with shaking at 250 r.p.m.
9|
The next day, take a 0.5-ml sample of the overnight bacterial culture and confirm that the optical density reading at 600 nm (OD 600 ) is between 4 and 5, and that the pH is 6.5.
10|
Combine 400 ml of the minicircle induction broth (see REAGENT SETUP) with 400 ml of the overnight culture into a 2-liter Erlenmeyer flask. Incubate at 32 °C with shaking at 250 r.p.m. for > 5 h.  crItIcal step Longer incubation periods of up to 9 h will yield minicircle DNA of greater purity.
11|
Pellet bacterial cells by centrifugation at 6,000g for 15 min at 4 °C.
12|
Discard supernatant and resuspend the bacterial pellet in 100 ml of Qiagen Buffer P1 (Qiagen Buffers P1, P2, P3 and EB are included in the HiSpeed maxi prep kit). Follow the maxi prep kit protocol per the manufacturer's instructions, but use double the volume of buffers P1, P2 and P3 (100 ml each). Elute DNA using 200 µl of Buffer EB or Tris-EDTA buffer (pH 8).
13|
Measure DNA concentration and purity using a spectrophotometer. Minicircle DNA is now ready for subsequent transfection. For further confirmation of the identity and integrity of minicircle DNA preparation, dilute a sample (0.5 µg) in an appropriate volume of 10× DNA loading dye and electrophorese on a 0.8% (wt/vol) agarose gel at 100 V for 70 min alongside a DNA ladder. Verify that a clean, solitary 5.6-kb band is present with no smaller bands indicating nicked or degraded DNA.  pause poInt Minicircle DNA preparations can be frozen in 5-µg aliquots at − 20 °C indefinitely. Avoid repeated freezethaw cycles.
Derivation of hascs • tIMInG 3 d (days 1-3) 14|
Obtain an adipose tissue sample by liposuction aspiration. ! cautIon Adipose tissue should be obtained by a surgeon or other appropriately trained physician. Informed consent should be obtained from the individual in accordance with institutional and international patient protection guidelines.
15|
Immediately place the adipose tissue specimen on ice.
16| Prepare four 50-ml conical tubes containing 25 ml of serial dilutions of povidone-iodine (Betadine) and PBS in ratios of 1:0 (undiluted Betadine), 1:1, 1:2 and 1:5. Wash the specimen by immersing it sequentially in each dilution for 5 s each.
17| Wash the specimen twice by immersion in 25 ml PBS in two separate 50-ml conical tubes.
18|
Place the specimen in a fresh 50-ml conical tube and measure the volume of the tube occupied by adipose tissue (~10 to 15 ml). Digest the tissue by adding an equal volume of 0.075% (wt/vol) Type II collagenase (see REAGENT SETUP). Incubate the digestion mixture in a 37 °C water bath with agitation at 125 r.p.m. for 30 min. 21| Aspirate the supernatant. Resuspend the pellet in 5 ml of hASC medium. Count the cells using an automated cell counter to verify that cell yield is ~1 to 5 × 10 6 cells.
22|
Filter the resuspended cells through a 100-µm cell strainer into a 15-ml conical tube.
23|
Add hASC medium to a total volume of 15 ml. Seed the entire 15-ml hASC cell suspension (~1 to 5 × 10 6 cells) on a 150-mm tissue culture dish for further expansion in a humidified incubator at 37 °C, 5% CO 2 . Primers 1-16 may be used for qPCR analysis of resulting hiPSC clones. Primer pairs specific for the endogenous transcript (3 and 4, 7 and 8, 11 and 12, 15 and 16) anneal to the untranslated region (UTR) of the transcript, which is absent on the minicircle-derived transcript. Used in conjunction, primers 2 and 5 amplify a specific 1.1-kb region that is unique to the minicircle construct as shown in Figure 3 . These two primers can be used to screen genomic DNA for integration of the minicircle-derived transgene as described (Steps 62-65). Primer 17 anneals to the CMV promoter transcriptional start site and may be used for sequence verification of the pMC.
LGNSO plasmid.
 crItIcal step hASCs can be passaged and expanded using standard cell culture techniques 26 . Our laboratory uses TrypLE Express reagent for digestion and split ratios of 1:4 every 3-5 d. hASCs may be placed in a cryopreservation solution (10% DMSO, 90% FBS) in aliquots of 2 × 10 5 cells per cryovial and immersed in liquid nitrogen indefinitely.  crItIcal step For optimal hiPSC generation efficiency, electroporate hASCs within three passages to minimize replicative senescence. : hasc transfection 1 • tIMInG 3 d (days 4-6 ) 24| Aspirate hASC medium from the 150-mm dish containing hASCs at ~70% confluency. Add 10 ml PBS and rock the plate to wash. Aspirate the PBS.
Induction of pluripotency
25| Add 2 ml TrypLE Express. Incubate at 37 °C for 2-5 min until cells round up and detach.
26| Add 4 ml of hASC growth medium to stop enzymatic digestion. Pipette the cell suspension up and down to wash all hASCs off the plate. Pipette the cell suspension into a 15-ml conical tube. Wash the 150-mm dish with another 4 ml of hASC medium and add it to the 15-ml conical tube. Count cells using an automated cell counter.
27| Pellet 1-2 × 10
6 hASCs by centrifugation at 200g for 5 min.
28|
Aspirate the supernatant completely. Gently resuspend the hASC pellet in 100 µl of Nucleofector Solution R.  crItIcal step Ensure that Nucleofector Solution R is at room temperature (25 °C). Ensure that supplement has been added to the solution per the manufacturer's instructions.
29| Add 5 µg of minicircle DNA from
Step 13 to the cell suspension.
30| Gently transfer the cell-DNA suspension to a cuvette using a micropipette. Close the cuvette with the cap. Place the cuvette in the Lonza Nucleofector device and execute program 'U-023' .
31|
Gently remove the cuvette from the device after completion of the program.
32|
Add ~500 µl of hASC medium (preferably prewarmed to 37 °C) to the cuvette using the plastic pipette. Next, use the same plastic pipette to gently transfer the cell suspension to a 150-mm dish. Avoid repeated aspiration of the sample. Carefully distribute the cells on the 150-mm dish by extremely gentle rocking. Place in 37 °C incubator for expansion.
33|
The next day, aspirate hASC medium containing non-viable cells. Add fresh hASC growth medium. Place 150-mm dish in 37 °C incubator overnight.
34|
The next day, aspirate hASC medium. Wash with PBS.
35| Add 2 ml of TrypLE Express. Incubate at 37 °C for 2-5 min until cells round up and detach from the plate. 37| Isolate 1 × 10 5 EGFP + cells by flow cytometry 23, 24 . Set the sorting gate specifically for green fluorescence with a 488-nm laser for EGFP, and maximize yield of EGFP + cells (~2% to 10% of the population). Pellet sorted cells by centrifugation at 1,200g for 5 min. Aspirate FACS buffer supernatant. Resuspend EGFP + hASC pellet in 4 ml hASC medium. Split cells into two wells of a six-well tissue culture plate (2 ml per well). Place in 37 °C incubator overnight.  crItIcal step Return hASCs to a humidified 37 °C incubator as quickly as possible to maximize cell viability. Be sure to have added penicillin-streptomycin antibiotic to medium to reduce the risk of contamination after the cell sorting procedure. ? troublesHootInG Induction of pluripotency: hasc transfection 2 • tIMInG 2 d (days 7-8) 38| Dilute 10 µg of minicircle DNA from Step 13 in 500 µl of Opti-MEM in a 1.5-ml microcentrifuge tube.
39|
Add 20 µl of Lipofectamine 2000 to 500 µl of Opti-MEM in a separate 1.5-ml microcentrifuge tube. Incubate at room temperature for 5 min.
40|
Add the Lipofectamine-containing solution to the DNA-containing solution gently and incubate at room temperature for 15-20 min.
41|
Aspirate hASC medium from the six-well plate containing hASCs (from Step 37). Add 2 ml PBS per well and rock the plate back and forth to wash. Aspirate the PBS. Next, add 1 ml of fresh hASC medium per well.
42|
Add 500 µl of the Lipofectamine-DNA solution to each well. Medium does not need to be refreshed, but if desired, wait until at least 4 h have elapsed since the addition of the Lipofectamine-DNA solution before refreshing the medium. Incubate overnight in a humidified incubator at 37 °C.
43|
The next day, aspirate medium from the wells containing hASCs. Replace with 2 ml of fresh hASC medium. Return to the incubator overnight.
Induction of pluripotency: hasc transfection 3 • tIMInG 1 d (day 9)
44| Repeat Steps 38-43. Figure 4b shows representative images of reprogramming hASCs during the transfection procedure. ~20% of the hASCs will remain EGFP + by day 10 of the procedure (Fig. 4c) .
45|
The next day, thaw one vial containing 5 × 10 6 cryopreserved iMEFs (irradiated MEFs, isolated from CF1 mice) by gently swirling in 37 °C water bath until most, but not all, of the contents have thawed.
46| Transfer 10 ml of hASC medium to an empty 15-ml conical tube. Slowly add iMEF cell suspension to the conical tube using a micropipettor. 50| Aspirate hASC medium from the 100-mm gelatin-coated dish containing iMEFs. Add 6 ml of PBS, wash by rocking back and forth, and aspirate PBS. Add 8 ml of hiPSC medium to the dish.
51|
Add 500 µl of hiPSC medium to each well of the six-well plate to stop enzymatic digestion. Gently pipette the solution over the surface of the well 5 or 6 times to detach all hASCs.
52|
Transfer the hASC cell suspension from the six-well plate to the 100-mm dish containing the iMEF feeder layer. Rock the cell suspension in several quick back-and-forth motions, then carefully place the 100-mm dish in the humidified incubator at 37 °C overnight. (Fig. 4) . Surrounding unreprogrammed or partially reprogrammed hASCs may appear EGFP + . Between 5 and 15 hiPSC colonies are expected from 2 × 10 5 EGFP + hASCs isolated during FACS (Step 37).
56|
When mosaic EGFP colonies reach a size of 0.5-1.0 mm in diameter, they can be cut into small clumps using a pulled Pasteur pipette. Subsequently, they can be picked up using a micropipettor set at 2 µl and then transferred to the wells of a 6-well plate containing fresh iMEFs for subcloning culture. This subcloning procedure may be repeated until EGFP + cells are completely absent. hiPSC clones can then be cultured and expanded according to standard hESC/hiPSC culture techniques 27, 28 . ? troublesHootInG screening of resulting hipsc clones for genomic integration • tIMInG 1 d 57| Isolate genomic DNA from one well of a 50-70% confluent six-well plate of hiPSCs with the ArchivePure DNA extraction kit, following the manufacturer's instructions. Also isolate total DNA from a cell line (e.g., HEK 293 cells) that has been transfected with the minicircle reprogramming cassette as a positive control.  pause poInt DNA preparations can be frozen at 4 °C for 3 months or − 20 °C indefinitely. Avoid repeated freeze-thaw cycles.
58|
Add the following components to a 0.2-ml PCR tube:
Genomic DNA 500 ng 10 µM primer 2 ( 
65|
Analyze cycle threshold (C T ) values for gene expression fold change using the ∆∆C T method 29 or perform gel electrophoresis of PCR products on a 1% (wt/vol) agarose gel (Fig. 4) . characterization of hipsc clones: immunocytochemistry • tIMInG 1 d 66| Aspirate the medium from one well of 50-70% confluent six-well plate of established hiPSCs.
67| Wash the cells with 2 ml of PBS.
68| Add 2 ml of PBS containing 10% formalin and fix the cells by incubation at room temperature for 10 min.
69| Wash the cells once with 2 ml of PBS.
70|
Aspirate the PBS and add 1 ml of PBS containing 1% (wt/vol) bovine serum albumin and 0.1% (vol/vol) Triton X-100. Incubate 45 min at room temperature.  crItIcal step Exclude Triton X-100 if staining cell surface markers, such as Tra-1-60, Tra-1-81 or SSEA-4. Triton X-100 is only necessary for staining of intracellular antigens such as OCT4, NANOG and SOX2.
71|
Aspirate the blocking solution and add 1 ml of the primary antibody diluted to the appropriate concentration. Incubate overnight at 4 °C.
72| Wash the cells three times for 5 min each with PBS.
73| Add 1 ml of secondary antibody conjugated to Alexa Fluor 488 or 546 supplemented with 4,6-diamidino-2-phenylindole (DAPI) at 1 µg ml − 1 and incubate for 45 min in the dark.
74|
Wash secondary antibody twice with 2 ml of PBS.
75|
Observe the cells with a fluorescent microscope equipped with the appropriate filters.
? troublesHootInG Troubleshooting advice can be found in table 2. Use high-quality DNA preparations. Store DNA at − 20 °C and avoid repeated freeze-thaw cycles as this may cause strand nicking and degradation
Partial reprogramming
Choose high-quality clones. Colonies with good hESC morphology are tightly compacted with sharp borders and they contain cells with prominent, large, round nucleoli and scant cytoplasm. Use freshly prepared medium and ensure that the appropriate amount of bFGF has been added
• tIMInG
Step 1-13, Preparation of minicircle DNA: 3 d
Step 14-23, Derivation of hASCs: 3 d
Step 24-48, Induction of pluripotency: 7 d
Step Figure 4c . Picked hiPSC clones will stain positively for pluripotency markers (Tra-1-60, SSEA-4), express high transcript levels of pluripotency genes (OCT4, SOX2, NANOG and TGFI (also known as CRIPTO)), and display hESC-like morphology, such as large, round nucleoli and scant cytoplasm (Fig. 4) . We have successfully derived 22 hiPSC lines using this protocol from three adult donors. We calculate our reprogramming efficiency using this technique as ~0.005%, although any such calculation may be obviated by the splitting of cells during the procedure.
